XML 16 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2020
Stockholders' Equity Note [Abstract]  
Range of warrant prices per share for shares under warrants and the weighted average contractual life
At March 31, 2020 and December 31, 2019, the weighted average warrant exercise price per share for common stock underlying warrants and the weighted average contractual life was as follows:
 
 
Number of
Warrants
 
Weighted
Average
Exercise Price
Per Share
 
Weighted Average Remaining Contractual Life
 
Number of
Warrants
Exercisable
 
Weighted
Average Price
Per Share
 
 
 
 
 
 
 
 
 
 
 
Outstanding December 31, 2019
 
28,926

 
$
9.80

 
3.66
 
28,926

 
$
9.80

Outstanding March 31, 2020
 
28,926

 
$
9.80

 
3.41
 
28,926

 
$
9.80

Schedule of activity under all stock option plans
Activity under all stock option plans was as follows:
 
 
Number of
Options
 
Weighted
Average
Exercise Price
per Share
 
Aggregate Intrinsic Value (in Thousands)
Outstanding December 31, 2019
 
1,802,463

 
$
6.75

 
 
Granted
 
191,667

 
0.98

 
 
Expired
 
(317,992
)
 
8.19

 
 
Outstanding March 31, 2020
 
1,676,138

 
$
5.81

 
$

Total vested and exercisable
 
1,266,859

 
$
6.72

 
$

Schedule of restricted stock award activity under the plan
Restricted common stock award activity under the plan was as follows:
 
 
Number of Shares
 
Weighted Average Fair Value
Unvested December 31, 2019
 
4,436,928

 
$
1.54

Granted
 
225,000

 
1.39

Vested
 
(593,644
)
 
0.69

Forfeited
 
(146,676
)
 
1.30

Unvested March 31, 2020
 
3,921,608

 
$
1.67

Assumptions used to estimate the fair value of options at date of grant
The fair value of options at date of grant was estimated using the Black-Scholes option pricing model, based on the following assumptions:

 
 
Three Months Ended March 31,
 
 
2020
 
2019
Risk-free interest rate
 
1.49% - 1.63%
 
N/A
Expected term (in years)
 
6.25
 
N/A
Dividend yield
 
—%
 
N/A
Expected volatility
 
55.92%
 
N/A
Summary of stock-based compensation
The following is a summary of stock-based compensation expense (in thousands):
 
 
Three Months Ended March 31,
 
 
2020
 
2019
Cost of revenues
 
$
11

 
$
166

Sales and marketing
 
112

 
81

Research and development
 
134

 
257

General and administrative
 
509

 
644

 
 
$
766

 
$
1,148